NRIX Stock Price Today (October 2026) — Nurix Therapeutics, Inc. Analysis & Key Metrics 2026-10-20
Nurix Therapeutics, Inc. (NRIX) is trading at $26.10, up 4.69% today (as of October 2026). The stock continues to show sustained strength above key moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $34.50 (32.2% upside).
- Volatility is moderate (38.48% annualized), implying notable price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (8426.30% YoY) alongside competitive pressures in the Biotechnology space.
NRIX Stock Analysis: Key Metrics & Valuation (October 2026)
Concise, actionable data for investors
Nurix Therapeutics, Inc. - Historical Price & Volume
- Price
- Volume
- Latest price
Market Cap
Enterprise Value: $1.87B
P/E Ratio
Forward P/E: N/A
Revenue Growth
Year over Year
Analyst Target
+32.2% upside potential
Key Investor Questions About NRIX
What investors need to know before buying
Based on current market data, NRIX presents a overbought technical setup with looking solid fundamentals.
- Technicals say: Overbought (RSI 70.96)
- Fundamentals say: Looking solid (debt and growth supportive)
NRIX's growth trajectory depends on its ability to expand within the Biotechnology sector while managing margin pressures.
- Future growth will depend on performance in core Biotechnology operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for NRIX investors include debt exposure and competitive dynamics in the Biotechnology industry.
- $65.33M in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Biotechnology.
52-Week Trading Range
Over the past year, NRIX stock traded between $10.15 and $28.23 and currently trades near the high end of that range. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 38.48% annualized volatility and β=1.44, the stock exhibits high sensitivity to market moves—making NRIX suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
Lower institutional support combined with high short selling points to negative sentiment.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines, coverage and TickZen analysis
Market news
Big Pharma Is Pouring Billions Into a New Class of ‘Protein Degrader’ Drugs
Nurix Therapeutics Insider Sold Shares Worth $528,528, According to a Recent SEC Filing
Nurix Therapeutics' Enterprise Value Remains Underappreciated, RBC Capital Markets Says
Cathie Wood Has Sold Nearly $18 Million of Meta in Days -- Here's What It Means
Latest TickZen Insights
All insights →No TickZen article on NRIX yet. Our newest analysis:
Explore More Analysis for NRIX
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Earnings snapshot
No upcoming report date yet
Frequently Asked Questions
Common investor questions about Nurix Therapeutics, Inc.
Nurix Therapeutics, Inc. (NRIX) is currently trading at $26.10. The RSI (14-day) is at 71.0, indicating overbought territory (potentially overheated). Wall Street analysts have a consensus "strong_buy" recommendation. The mean analyst price target of $34.50 implies 32.2% upside from current levels. Volatility is moderate at 38.5% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Nurix Therapeutics, Inc. (NRIX): The trailing P/E ratio is 10.28, which is below the market average of ~20-22, suggesting the stock may be undervalued relative to peers. Price-to-Book is 2.94. Price-to-Sales is 4.06. Valuation should be compared to Biotechnology industry peers for context, as different sectors trade at different multiples.
Based on 14 analysts covering NRIX, the consensus price target is $34.50. This represents a 32.2% upside from the current price of $26.10. The range spans from a low target of $25.00 to a high target of $45.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "strong_buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Nurix Therapeutics, Inc. (NRIX) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Nurix Therapeutics, Inc. (NRIX) investors include: 1. Moderate volatility (38.5% annualized)—price swings are notable. 2. Elevated short interest (16.3% of float) suggests significant bearish sentiment. 3. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 4. Biotechnology sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Nurix Therapeutics, Inc.'s (NRIX) current debt and financial health profile: Total debt stands at $65.33M. The debt-to-equity ratio is 0.07x, which is conservative and indicates a strong balance sheet with low leverage. The current ratio is 8.44, indicating strong short-term liquidity. The quick ratio is 8.19. The company holds $1.05B in cash and equivalents. Free cash flow is negative at -$304.53M, which could limit the company's ability to manage debt obligations.